Therapeutic Solutions International, Inc. engages in the provision of immune modulation for the treatment of several specific diseases. The company is headquartered in Elk City, Idaho and currently employs 3 full-time employees. The company went IPO on 2008-06-09. The firm is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. The company has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. The company has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.
Follow-Up Questions
Who is the CEO of Therapeutic Solutions International Inc?
Mr. Timothy Dixon is the Chairman of the Board of Therapeutic Solutions International Inc, joining the firm since 2011.
What is the price performance of TSOI stock?
The current price of TSOI is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Therapeutic Solutions International Inc?
Therapeutic Solutions International Inc belongs to N/A industry and the sector is N/A
What is Therapeutic Solutions International Inc market cap?
Therapeutic Solutions International Inc's current market cap is $5122.71
